Molecular Profile Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
BRAF V600X colorectal cancer sensitive RAF Inhibitor (Pan) Vemurafenib + Cetuximab + Irinotecan Phase Ib/II Actionable In a Phase Ib trial, the addition of Zelboraf (vemurafenib) to Camptosar (irinotecan) plus Erbitux (cetuximab) improved progression-free survival (4.4 mo vs. 2.0 mo), and disease control rate (67% vs. 22%), compared to Camptosar (irinotecan) plus Erbitux (cetuximab) without Zelboraf (vemurafenib), in patients with BRAF V600-mutant colorectal cancer (J Clin Oncol 35, 2017 (suppl 4S; abstract 520)). detail...
BRAF V600X melanoma sensitive BRAF Inhibitor MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor AMG 232 + Trametinib + Dabrafenib Phase I Actionable In a Phase I trial, the combination therapy of AMG 232, Mekinist (trametinib), and Tafinlar (dabrafenib) in 6 patients with metastatic cutaneous melanoma harboring a BRAF V600 mutation resulted in 4 patients with a partial response and 2 patients with stable disease, and of the 6 patients, all experienced tumor reduction (J Clin Oncol 35, 2017 (suppl; abstr 2575)). detail...
BRAF V600X melanoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor RAF Inhibitor (Pan) Atezolizumab + Vemurafenib + Cobimetinib Phase Ib/II Actionable In a Phase Ib trial, the combination of Tecentriq (atezolizumab), Cotellic (cobimetinib), and Zelboraf (vemurafenib) resulted in antitumor efficacy in BRAF V600 positive melanoma patients, demonstrating an unconfirmed RECIST response in 85.3% (29/34) of patients, including 6 CRs and 23 PRs, and confirmed PRs in three patients (J Clin Oncol 35, 2017 (suppl; abstr 3063)). detail...
BRAF V600X melanoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor BKM120 + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the combination of Buparlisib (BKM120) and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152). 24265152
BRAF V600X thyroid cancer predicted - sensitive RAF Inhibitor (Pan) Vemurafenib Phase II Actionable In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in an overall response rate of 29% (2/7), with 1 complete response and 1 partial response, in patients with anaplastic thyroid cancer patients with BRAF V600 mutations (PMID: 26287849). 26287849
BRAF V600X melanoma sensitive BRAF Inhibitor MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Trametinib + Dabrafenib Phase Ib/II Actionable In a Phase I/II clinical trial, patients with BRAF V600 mutant melanoma (n=78) treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) had a median overall survival of greater than 2 years (PMID: 26811525). 26811525
BRAF V600X melanoma sensitive BRAF Inhibitor MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Trametinib + Dabrafenib Guideline Actionable Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for melanoma patients harboring a BRAF V600 activating mutation, as adjuvant treatment for patients with Stage III disease, or as systemic therapy for patients with unresectable or metastatic disease (NCCN.org). detail...
BRAF V600X melanoma sensitive RAF Inhibitor (Pan) MK2206 + Vemurafenib Preclinical - Cell culture Actionable In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152). 24265152
BRAF V600X cholangiocarcinoma sensitive RAF Inhibitor (Pan) Vemurafenib Phase II Actionable In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in partial response in 12% (1/8) and stable disease in 50% (4/8) of cholangiocarcinoma patients with BRAF V600 mutations (PMID: 26287849). 26287849
BRAF V600X melanoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Binimetinib Phase II Actionable In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587). 23414587
BRAF V600X melanoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor MK2206 + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the combination of MK2206 and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152). 24265152
BRAF V600X melanoma sensitive RAF Inhibitor (Pan) Vemurafenib Guideline Actionable Zelboraf (vemurafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org). detail...
BRAF V600X melanoma sensitive BRAF Inhibitor Dabrafenib Guideline Actionable Tafinlar (dabrafenib) therapy is included in guidelines for melanoma patients with unresectable or metastatic disease harboring BRAF V600 activating mutations, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org). detail...
BRAF V600X melanoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor RAF Inhibitor (Pan) Trametinib + Vemurafenib Preclinical - Cell culture Actionable In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152). 24265152
BRAF V600X melanoma sensitive BRAF Inhibitor ASN003 Preclinical - Pdx Actionable In a preclinical study, melanoma patient derived xenograft (PDX) model harboring a BRAF V600 mutation demonstrated antitumor activity when treated with ASN003 (J Clin Oncol 35, 2017 (suppl; abstr e14102)). detail...
BRAF V600X colorectal cancer no benefit RAF Inhibitor (Pan) Vemurafenib Phase II Actionable In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) in colorectal cancer patients with BRAF V600 mutations did not result in clinical benefit, with no patients achieving response, and 50% (5/10) demonstrating progressive disease (PMID: 26287849). 26287849
BRAF V600X melanoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor RAF Inhibitor (Pan) Selumetinib + Vemurafenib Preclinical - Cell culture Actionable In a preclinical study, the combination of Selumetinib (AZD6244) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152). 24265152
BRAF V600X melanoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor BKM120 + Selumetinib Preclinical - Cell culture Actionable In a preclinical study, the combination of Buparlisib (BKM120) and Selumetinib (AZD6244) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152). 24265152
BRAF V600X colorectal cancer sensitive BRAF Inhibitor MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Trametinib + Dabrafenib Phase Ib/II Actionable In a Phase Ib/II trial, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in partial response or better in 12% (5/43), including 1 complete response, and stable disease in 51% (22/43) of patients with BRAF V600-mutant colorectal cancer (PMID: 26392102). detail... 26392102
BRAF V600X melanoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor RAF Inhibitor (Pan) Vemurafenib + Cobimetinib Guideline Actionable Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in melanoma guidelines for patients with metastatic or unresectable disease harboring a BRAF V600 activating mutation (NCCN.org). detail...
BRAF V600X melanoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor RAF Inhibitor (Pan) Vemurafenib + Cobimetinib Phase III Actionable In a Phase III trial, combination treatment with Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months compared to 7.2 months with Zelboraf (vemurafenib) alone among patients with BRAF V600-mutated metastatic melanoma (PMID: 27480103; NCT01689519). 27480103
BRAF V600X melanoma sensitive RAF Inhibitor (Pan) BKM120 + Vemurafenib Preclinical - Cell culture Actionable In a preclinical study, the combination of Buparlisib (BKM120) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152). 24265152
BRAF V600X colorectal cancer sensitive RAF Inhibitor (Pan) Vemurafenib + Cetuximab Phase II Actionable In a Phase II clinical trial, treatment with the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) resulted in an overall response rate of 4% (1/26), stable disease in 69% (18/26), and a median progression-free survival of 3.7 months in patients with BRAF V600-mutant colorectal cancer (PMID: 26287849). 26287849
Clinical Trial Phase Therapies Title Recruitment Status
NCT02039947 Phase II Trametinib + Dabrafenib Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain Completed
NCT01603212 Phase Ib/II Aldesleukin + Vemurafenib + IFN A2b Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor Completed
NCT01436656 Phase I Encorafenib A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma Active, not recruiting
NCT03005639 Phase II Vemurafenib + Cobimetinib ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma Withdrawn
NCT03149029 Phase II Pembrolizumab + Dabrafenib + Trametinib Pembrolizumab + Trametinib Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma Recruiting
NCT01902173 Phase Ib/II Trametinib Dabrafenib + GSK2141795 GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Suspended
NCT03178851 Phase I Atezolizumab + Cobimetinib A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy Recruiting
NCT02278133 Phase Ib/II LGK974 + LGX818 + Cetuximab Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations Completed
NCT01942993 Phase II Vemurafenib The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma Terminated
NCT01543698 Phase Ib/II Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors Active, not recruiting
NCT01813214 Phase II Vemurafenib The Effects of Vemurafenib on Immunity in Patients With Melanoma Terminated
NCT02296112 Phase II Trametinib Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations Active, not recruiting
NCT03446157 Phase II Palbociclib + Cetuximab Palbociclib and Cetuximab in Metastatic Colorectal Cancer Recruiting
NCT01777776 Phase Ib/II Encorafenib Encorafenib + Ribociclib Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Terminated
NCT02145143 Phase I Vemurafenib Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib Active, not recruiting
NCT01656642 Phase I Atezolizumab + vemurafenib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma Active, not recruiting
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Nivolumab + Ipilimumab Vemurafenib + Cobimetinib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting
NCT01767623 Phase I Vemurafenib A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients Completed
NCT03087071 Phase II Panitumumab Trametinib Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer Recruiting
NCT02908672 Phase III Vemurafenib + Cobimetinib Atezolizumab + Vemurafenib + Cobimetinib A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma Active, not recruiting
NCT02974803 Phase II Trametinib + Dabrafenib Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases Recruiting
NCT02124772 Phase I Trametinib Trametinib + Dabrafenib Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations Recruiting
NCT01519323 Phase I Vemurafenib BRIM-P Terminated
NCT03301636 Phase II Pembrolizumab Indoximod + Nivolumab Indoximod + Pembrolizumab Nivolumab A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107) Recruiting
NCT01659151 Phase II Fludarabine Vemurafenib Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Active, not recruiting
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Olaparib Selumetinib Ensartinib Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas Recruiting
NCT01701037 Phase II Trametinib + Dabrafenib Dabrafenib Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery Terminated
NCT01843738 Phase I Vemurafenib Radiation Use During Vemurafenib Treatment Withdrawn
NCT01954043 Phase I Dabrafenib + Rabeprazole + Rifampin A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors Completed
NCT01835184 Phase I Cabozantinib + Vemurafenib Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery Terminated
NCT03543969 Phase I Vemurafenib + Cobimetinib Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma Recruiting
NCT01677741 Phase I Dabrafenib The Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Pediatric Subjects Recruiting
NCT03592641 Phase II Savolitinib Volitinib in Treating Participants With MET Amplified Metastatic or Unresectable Colorectal Cancer Not yet recruiting
NCT02145910 Phase I Vemurafenib Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases Withdrawn
NCT03442569 Phase II Ipilimumab + Nivolumab + Panitumumab PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Recruiting
NCT02091141 Phase II Erlotinib Alectinib Vemurafenib + Cobimetinib Pertuzumab + Trastuzumab Vismodegib Atezolizumab My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Recruiting
NCT01619774 Phase II GSK1120212 + Dabrafenib An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor Completed
NCT02068079 Phase I Vemurafenib + Trientine A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma Withdrawn
NCT01946789 Phase I ALT-803 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors Active, not recruiting
NCT02967692 Phase III Dabrafenib + Trametinib + PDR001 Trametinib + Dabrafenib A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma Recruiting
NCT02906059 Phase I MK-1775 + Irinotecan Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Recruiting
NCT01894672 Phase II Encorafenib BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation Completed
NCT01844674 Phase I Vemurafenib + Tizanidine A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies Completed
NCT01739764 Phase III Vemurafenib An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol Active, not recruiting
NCT01524978 Phase II Vemurafenib Cetuximab A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers Completed
NCT01820364 Phase II Binimetinib + Encorafenib Encorafenib + Ribociclib Encorafenib + BKM120 BGJ398 + Encorafenib Capmatinib + Encorafenib LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma Terminated
NCT03026517 Phase I Dabrafenib + Trametinib + Phenformin Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma Recruiting
NCT03377361 Phase Ib/II Nivolumab + Ipilimumab Ipilimumab + Nivolumab + Trametinib An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread Recruiting
NCT01981187 Phase II Encorafenib LGX818 for Patients With BRAFV600 Mutated Tumors Completed
NCT01974258 Phase I Onartuzumab + Vemurafenib Onartuzumab + Cobimetinib Onartuzumab + Cobimetinib + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn
NCT02159066 Phase II Binimetinib + Encorafenib + Ribociclib Binimetinib + Encorafenib LGX818 + MEK162 + INC280 LGX818 + MEK162 + BKM120 LGX818 + MEK162 + BGJ398 LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Active, not recruiting
NCT01826448 Phase I Pexidartinib + Vemurafenib A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma Terminated
NCT02094872 Phase II Doxorubicin Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Active, not recruiting
NCT02230306 Phase II Vemurafenib + Cobimetinib Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases Terminated
NCT03829410 Phase Ib/II Bevacizumab + FOLFIRI + Onvansertib Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation Not yet recruiting
NCT03273153 Phase III Pembrolizumab Atezolizumab + Cobimetinib A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma Recruiting
NCT01787500 Phase I Vemurafenib + Cetuximab + Irinotecan Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers Active, not recruiting
NCT02263898 Phase II Binimetinib + Encorafenib Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations Withdrawn
NCT01738451 Phase I Dabrafenib A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors Completed
NCT01907802 Phase I Dabrafenib Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction Terminated
NCT02456701 Phase I CDX-3379 + Vemurafenib Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 Completed
NCT02036086 Phase II Vemurafenib + Cobimetinib Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases Recruiting
NCT02723006 Phase I MLN2480 + Nivolumab MLN1202 + Nivolumab Ipilimumab + Nivolumab + Vedolizumab Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma Terminated
NCT01683188 Phase III Aldesleukin + Vemurafenib HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated
NCT02961283 Phase I ASN003 Study of ASN003 in Subjects With Advanced Solid Tumors Active, not recruiting
NCT02082665 Phase I Dabrafenib + Rosuvastatin + Midazolam Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam Completed
NCT03220035 Phase II Vemurafenib Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations Recruiting